Journal article
MM-128: Carfilzomib, Dexamethasone, and Daratumumab (KdD) Versus Carfilzomib and Dexamethasone (Kd) in Relapsed or Refractory Multiple Myeloma (RRMM): Subgroup Analysis of the Phase 3 CANDOR Study by Number of Prior Lines of Therapy (pLOTs) and Prior Therapies
Hang Quach, Ajay Nooka, Olga Samoylova, Christopher Venner, Kihyun Kim, Thierry Facon, Andrew Spencer, Saad Usmani, Sebastian Grosicki, Kenshi Suzuki, Sosana Delimpasi, Katja Weisel, Mihaela Obreja, Anita Zahlten-Kumeli, Maria-Victoria Mateos
Clinical Lymphoma Myeloma and Leukemia | Elsevier BV | Published : 2020
Abstract
Context: RRMM requires effective and tolerable treatments, particularly for those exposed or refractory to lenalidomide (LEN) or bortezomib (BOR).The CANDOR trial found KdD improved progression-free survival (PFS) vs Kd (hazard ratio [HR] 0.63; 95% confidence interval [CI], 0.46–0.85) in RRMM. Objective: To determine whether outcomes varied by number of pLOT or prior LEN or BOR treatment, we undertook subgroup analyses of CANDOR. Design: RRMM pts were randomized 2:1 to KdD or Kd (parallel-assignment, open-label; 2017–2019; median follow-up, 16.9 and 16.3 mo, respectively). Setting: Multicenter trial. Patients: Adult pts with measurable disease and 1–3 pLOTs; prior carfilzomib permitted. Inte..
View full abstract